ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 244 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5 | -37.5% | 200 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $8 | +33.3% | 200 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $6 | 0.0% | 200 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $6 | -99.9% | 200 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $7,000 | -12.5% | 200 | 0.0% | 0.00% | -50.0% |
| Q2 2022 | $8,000 | -11.1% | 200 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $9,000 | -30.8% | 200 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $13,000 | +8.3% | 200 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $12,000 | -58.6% | 200 | -42.9% | 0.00% | -60.0% |
| Q2 2021 | $29,000 | +26.1% | 350 | 0.0% | 0.01% | +25.0% |
| Q1 2021 | $23,000 | -57.4% | 350 | -50.0% | 0.00% | -63.6% |
| Q4 2020 | $54,000 | +80.0% | 700 | 0.0% | 0.01% | +57.1% |
| Q3 2020 | $30,000 | 0.0% | 700 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $30,000 | +50.0% | 700 | 0.0% | 0.01% | +16.7% |
| Q1 2020 | $20,000 | -68.3% | 700 | -30.0% | 0.01% | -62.5% |
| Q4 2019 | $63,000 | +125.0% | 1,000 | 0.0% | 0.02% | +100.0% |
| Q3 2019 | $28,000 | – | 1,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Financial Corp/CA | 820,320 | $20,836,128 | 14.83% |
| Aquilo Capital Management, LLC | 1,018,474 | $25,869,240 | 10.72% |
| Rokos Capital Management LLP | 1,675,921 | $41,537,702 | 3.07% |
| COMMODORE CAPITAL LP | 575,000 | $14,605,000 | 2.22% |
| Privium Fund Management B.V. | 259,036 | $6,579,514 | 2.21% |
| JOHNSON & JOHNSON | 247,598 | $6,288,989 | 2.05% |
| WEALTH EFFECTS LLC | 156,810 | $3,982,976 | 2.04% |
| M28 Capital Management LP | 67,400 | $1,711,960 | 1.94% |
| Evolutionary Tree Capital Management, LLC | 51,878 | $1,317,701 | 1.83% |
| Avidity Partners Management LP | 1,741,300 | $44,229,020 | 1.47% |